Fairvalue-Calculator Fairvalue-Calculator
EN DE

Item 9 Labs Corp (INLB) Fair Value & Analysis

Healthcare · US · Market cap $10.2K

Price$0.0001
Fair Value$0.0001
Upside+0.0%
Quality89/100
Evidence: Low Range $0.0001 – $0.0001

Fair value as of: Jun 26, 2026

Analysis

Item 9 Labs Corp (INLB) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. It operates through Cultivation, Franchising, and Corporate segments. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells medical and adult-use cannabis dispensary franchises under the Unity Rd brand name. Item 9 Labs Corp. is headquartered in Phoenix, Arizona.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Item 9 Labs Corp (INLB) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001 — about +0% (undervalued). Model-based estimate, not financial advice.
What is the fair value of INLB?
Our 21-model fair value for Item 9 Labs Corp is $0.0001 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0001.
What is the quality score of INLB?
Item 9 Labs Corp has a Quality Score of 89/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.